Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa (Q83288649)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 January 2012

Language	Label	Description	Also known as
English	Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa	scientific article published on 20 January 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

based on heuristic

inferred from title

author name string

Hidehiro Itonaga

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Hideki Tsushima

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Tomoko Hata

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Emi Matsuo

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Daisuke Imanishi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Yoshitaka Imaizumi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Yasuhisa Kawaguchi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Takuya Fukushima

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Yuko Doi

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Sayaka Mori

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Shimeru Kamihira

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Masao Tomonaga

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Yasushi Miyazaki

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

20 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

95

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

209-213

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22262141%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted therapy and the T315I mutation in Philadelphia-positive leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22262141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83288649&oldid=2221369820"